Everything below concerns Angiotensin IV analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Parmotrema perlatum is globally widespread lichen found on all continents except Antarctica and predominantly in oceanic areas in Europe, primarily grows on bark and occasionally on siliceous rocks amongst mosses. While it is seeing an increase in the Netherlands due to global warming, it is critically endangered in the Czech Republic, Slovakia, and Poland due to susceptibility to air pollution, and is listed as extinct in certain regional Red Data Books due to a lack of recent findings. In contrast, it has been increasing in sightings in the Netherlands, a phenomenon attributed to both global warming decreases in the levels or air pollution in recent decades. Its recent recurrence in Hungary, particularly on some unusual hosts (Catalpa bignonioides, Prunus serotina, and Robinia pseudoacacia) have been suggested as a possible consequence of "a recolonisation process, due to the improving air quality".
=== Legal status === The FDA granted the application for pegcetacoplan orphan drug designation. In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aspaveli, intended for the treatment of adults with paroxysmal nocturnal hemoglobinuria. The applicant for this medicinal product is Swedish Orphan Biovitrum AB (publ). Pegcetacoplan was approved for the treatment of paroxysmal nocturnal hemoglobinuria in the European Union in December 2021. FDA approved Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration (ARMD) in February 2023. In June 2024, the CHMP recommended the refusal of a marketing authorization for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration. The manufacturer requested a re-examination in July 2024. In September 2024, the CHMP continued to refuse a marketing authorization after a re-examination.
Archaeological excavations in Germany and Britain show that in addition to the meat supplied by the army, soldiers hunted animals such as beavers, badgers, foxes, and wolves while on campaign. Most grain rations were issued whole, meaning that soldiers had to mill and process the grain by themselves. However, grain rations also included hardtack biscuits called buccellatum, which were baked twice to remove the moisture, making them harder to spoil. These biscuits may have been ground into flour. Roman soldiers ate twice a day. The first meal, the prandium, likely required no cooking. The main meal was the cena, during which soldiers cooked and ate communally with their contubernium. Supply of water faced logistical problems. Roman military camps were typically built near water sources and soldiers were expected to collect their water for the days' march in a waterskin that was stored in the sarcina. As fresh water was not always available, water was often transported in barrels. However, this could result in the water becoming tainted, and so it was mixed with wine and vinegar to create posca, a drink which became popular among the urban poor as well as the army. During the Byzantine era, soldiers were trained in sustaining their food supplies for as long as 20 days, with many also carrying small hand mills to grind grain to make paximathia. In ancient Greece, hoplites were expected to bring foodstuffs and wine with them when going on campaigns. However, as the amount they could carry was limited, armies had to live off the land.
Sources: en.wikipedia.org
=== DNA repair === Lymphoblastoid cell lines established from blood samples of centenarians have significantly higher activity of the DNA repair protein PARP (Poly ADP ribose polymerase) than cell lines from younger (20 to 70 years old) individuals. The lymphocytic cells of centenarians have characteristics typical of cells from young people, both in their capability of priming the mechanism of repair after H2O2 sublethal oxidative DNA damage and in their PARP capacity. PARP activity measured in the permeabilized mononuclear leukocyte blood cells of thirteen mammalian species correlated with maximum lifespan of the species. These findings suggest that PARP mediated DNA repair activity contributes to the longevity of centenarians, consistent with the DNA damage theory of aging.
In the case of arsenic trioxide-induced apoptosis, two mechanisms play a significant role in increasing the levels of pro-apoptotic proteins. The first is related to the functioning of the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). NF-κB exists in the cytoplasm in an inactive state, in a complex with the specific reaction inhibitor IκB (IKK). This complex consists of two catalytic subunits – IKKα and IKKβ – and a regulatory unit IKKγ/NEMO. The phosphorylation and degradation of the inhibitor release NF-κB, which then translocates to the cell nucleus and activates genes responsible for producing "survival" proteins (such as p53, Bcl-2, and other inhibitors of apoptosis). NF-κB also protects cells from apoptotic stimulation involving the TNF-α receptor. Arsenic trioxide binds to the cysteine at position 179 of IKKβ, thus preventing the release of NF-κB. The absence of this protein in the cytoplasm allows for the induction of apoptosis via the extrinsic pathway and activates caspases 3 and 8. This mechanism has been observed not only in acute promyelocytic leukemia cells and Hodgkin lymphoma but also in patients with myelodysplastic syndrome. The second mechanism that increases the levels of pro-apoptotic proteins is the downregulation of bcl-2 gene transcription. This effect has been observed in HL-60 and NB4 human leukemia cells. In 2003, Japanese researchers discovered that arsenic trioxide induces apoptosis not only through the TNF-α receptor.
Soluble gas neurotransmitters are difficult to study because they act rapidly and are immediately broken down, existing for only a few seconds. The most prevalent transmitter is glutamate, which is excitatory at well over 90% of the synapses in the human brain. The next most prevalent is gamma-Aminobutyric Acid, or GABA, which is inhibitory at more than 90% of the synapses that do not use glutamate. Although other transmitters are used in fewer synapses, they may be very important functionally: the great majority of psychoactive drugs exert their effects by altering the actions of some neurotransmitter systems, often acting through transmitters other than glutamate or GABA. Addictive drugs such as cocaine and amphetamines exert their effects primarily on the dopamine system. The addictive opiate drugs act primarily as functional analogs of opioid peptides, which, in turn, regulate dopamine levels.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.